WHO Pharmaceuticals Newsletter No.3, 2016

OMS, 1 de julio de 2016

Tabla de contenidos
Regulatory  Matters
Afatinib maleate
Aripiprazole
Celecoxib
Chlorhexidine antiseptic non-prescription topical products
Denosumab
Edoxaban tosilate hydrate
Erlotinib
Febuxostat
Fexofenadine hydrochloride/pseudoephedrine hydrochloride combination
Fluoroquinolone antibacterial drugs
Gabapentin
Hepatitis C antivirals
Ibrutinib
Idelalisib
Ipilimumab
Levodopa containing products
Metformin
Moviprep® combination oral solution
Olanzapine
Oseltamivir phosphate
Peramivir hydrate
Pomalidomide
Proton pump inhibitors
Rivaroxaban
Saxagliptin and alogliptin containing products
Trabectedin
Vildagliptin and sitagliptin phosphate hydrate

Safety of Medicines
Aflibercept
Anticholinergic Drugs
Brintellix® (vortioxetine)
Canagliflozin
Fluconazole
Pertuzumab

Signal
Dabigatran and thromboembolism: analysis of case histories for risk factors
Febuxostat and allergic vasculitis

disponible en http://bit.ly/298dd2W